M3 muscarinic receptor and beta-2 adrenergic receptor — Drug Target

All drugs that target M3 muscarinic receptor and beta-2 adrenergic receptor — marketed and clinical-stage. Includes 2 drug classes acting on this target.

Drug classes

Long-acting muscarinic antagonist / Long-acting beta-2 agonist combination (LAMA/LABA) · LAMA/LABA combination (long-acting muscarinic antagonist/long-acting beta-2 agonist)

Marketed (1)

• umeclidinium bromide and vilanterol trifenatate · Chiesi Farmaceutici S.p.A. · Long-acting muscarinic antagonist / Long-acting beta-2 agonist combination (LAMA/LABA) · Respiratory / Pulmonology
  Umeclidinium is a long-acting muscarinic antagonist and vilanterol is a long-acting beta-2 agonist that together relax airway smooth muscle and improve airflow in chronic obstructive pulmonary disease.

Phase 3 pipeline (1)

• GSK573719/VI 125/25 · GlaxoSmithKline · LAMA/LABA combination (long-acting muscarinic antagonist/long-acting beta-2 agonist) · Respiratory/Pulmonology
  GSK573719/VI 125/25 is a combination of an inhaled long-acting muscarinic antagonist (LAMA) and long-acting beta-2 agonist (LABA) that relaxes airway smooth muscle and improves airflow in chronic obstructive pulmonary disease.